Valneva Stock Enters Oversold Territory After a 39% Decline Over Three Months

Significant Selling Pressure as Valneva Falls Below Support Level

Approaching the close, Valneva shows a decline of 5.31% compared to last Thursday's close at 2.71 euros. The stock thus falls below its support threshold at the same level of 2.71 euros, a signal that illustrates the magnitude of selling pressure. The RSI indicator, which measures the ratio between recent upward and downward movements, stands at 26, well below the usual oversold threshold of 30.

The Bollinger Bands confirm this reading: the price is moving in the lower part of the channel, only 17% above the lower boundary set at 1.91 euros, indicating extreme downward tension. The stock is also significantly below its 20, 50, and 200-day moving averages, positioned at 3.82, 4.15, and 3.88 euros respectively, indicating a bearish trend established over several weeks.

Valneva's Decline Amid a Generally Negative Session for the Health Sector in Paris

Valneva's decline occurs in a generally negative session for the Paris-listed health sector. Sanofi is down 2.22% and UCB loses 0.23%, while the CAC 40 drops 0.48% during the session, at 7,924 points. The SBF 120 drops in similar proportions.

With a beta of 0.34, Valneva's stock is theoretically less correlated with general market movements, which makes its decline all the more notable in its magnitude. The next milestone likely to provide new fundamental elements will be the publication of the first quarter 2026 results, scheduled for May 7, followed by the annual general meeting planned for June 1. The one-month volatility of the stock stands at 23.13%, a high level that reflects the uncertainty surrounding the current valuation of the vaccine biotech.